CN102164638A - 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 - Google Patents

组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 Download PDF

Info

Publication number
CN102164638A
CN102164638A CN2009801382462A CN200980138246A CN102164638A CN 102164638 A CN102164638 A CN 102164638A CN 2009801382462 A CN2009801382462 A CN 2009801382462A CN 200980138246 A CN200980138246 A CN 200980138246A CN 102164638 A CN102164638 A CN 102164638A
Authority
CN
China
Prior art keywords
hydroxycarbamoyl
diethyl
phenylcarbamoyloxymethyl
philadelphia
naphthalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801382462A
Other languages
English (en)
Chinese (zh)
Inventor
T·奥尔多尼
P·马斯卡尼
A伦巴迪
T·巴尔布伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CN102164638A publication Critical patent/CN102164638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801382462A 2008-09-29 2009-09-21 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 Pending CN102164638A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720 2008-09-29
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
US61/193,283 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
CN102164638A true CN102164638A (zh) 2011-08-24

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801382462A Pending CN102164638A (zh) 2008-09-29 2009-09-21 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途

Country Status (17)

Country Link
US (4) US20110294892A1 (enExample)
EP (1) EP2344253B1 (enExample)
JP (1) JP2012504112A (enExample)
KR (3) KR20170124640A (enExample)
CN (1) CN102164638A (enExample)
BR (1) BRPI0913699A2 (enExample)
CA (1) CA2738081C (enExample)
CY (1) CY1115255T1 (enExample)
DK (1) DK2344253T3 (enExample)
ES (1) ES2478827T3 (enExample)
HR (1) HRP20140499T1 (enExample)
IT (1) IT1392908B1 (enExample)
PL (1) PL2344253T3 (enExample)
PT (1) PT2344253E (enExample)
SI (1) SI2344253T1 (enExample)
SM (1) SMT201400087B (enExample)
WO (1) WO2010034693A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
TW201821105A (zh) 2016-10-20 2018-06-16 美商弗瑪治療公司 使用ｈｄａｃ１１抑制劑之方法
EP3583155B1 (en) * 2017-02-20 2024-05-08 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US20080194681A1 (en) * 2004-12-09 2008-08-14 Kalypsys, Inc. Novel Inhibitors of Histone Deacetylase for the Treatment of Disease
EP1910342A1 (en) * 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN101426903A (zh) 2005-12-09 2009-05-06 麻省理工学院 基于细胞核形态鉴定并靶向肿瘤干细胞的方法
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V GUERINI等: "The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F", 《LEUKEMIA》 *

Also Published As

Publication number Publication date
PT2344253E (pt) 2014-07-16
US9522127B2 (en) 2016-12-20
EP2344253A1 (en) 2011-07-20
JP2012504112A (ja) 2012-02-16
KR20170124640A (ko) 2017-11-10
CA2738081C (en) 2017-11-07
PL2344253T3 (pl) 2014-09-30
IT1392908B1 (it) 2012-04-02
CA2738081A1 (en) 2010-04-01
US20140039059A1 (en) 2014-02-06
CY1115255T1 (el) 2017-01-04
KR20160096721A (ko) 2016-08-16
BRPI0913699A2 (pt) 2017-06-13
DK2344253T3 (da) 2014-06-16
ITMI20081720A1 (it) 2010-03-30
EP2344253B1 (en) 2014-04-23
ES2478827T3 (es) 2014-07-23
US20110294892A1 (en) 2011-12-01
HRP20140499T1 (hr) 2014-07-04
SI2344253T1 (sl) 2014-08-29
US20210128512A1 (en) 2021-05-06
US20170049740A1 (en) 2017-02-23
SMT201400087B (it) 2014-09-08
WO2010034693A1 (en) 2010-04-01
KR20110069075A (ko) 2011-06-22

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
Lu et al. Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-α-induced inflammation in microglia cells
ES2410930T3 (es) Nuevos enfoques terapéuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante la modulación de la respuesta de estrés celular
US10973820B2 (en) Compounds for treatment of diseases related to DUX4 expression
JP2005525345A (ja) Ｔｒｘ媒介性疾患を処置する方法
CN103619168B (zh) 用于治疗白血病的组合物、方法和药盒
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2018528206A (ja) Ｍｄｍ２阻害剤およびその組み合わせ物
Passos et al. Involvement of phosphoinositide 3-kinase γ in the neuro-inflammatory response and cognitive impairments induced by β-amyloid 1–40 peptide in mice
Chang et al. Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR
JP2009527478A (ja) パーキンソン病の治療のための方法と組成物
Yamanaka et al. Map kinase c‐JUN N‐terminal kinase mediates PMMA induction of osteoclasts
US20110237663A1 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
JP2021187831A (ja) Ｓ−ヒドロキシクロロキンを用いたエリテマトーデスの治療
ES2239529B1 (es) Procedimiento de identificacion de los compuestos reguladores de la actividad tubulina desacetilasa de hdac6 y sus aplicaciones.
ES3028375T3 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
WO2025059029A1 (en) Methods of treating vexas syndrome
ES2589169B1 (es) Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos
AU2017263174A1 (en) Methods of treating diseases associated with ILC3 cells
Berenguer Roque et al. Xanthatin nanocrystals exert anti-inflammatory properties against TNFα-primed 2D monolayers and in 3D spheroids of human HT29 colorectal cancer cells
Guo et al. Mechanism of Activation of AMPK/P53-CyPD Signalling Pathway in Inhibiting Osteoblast Apoptosis Induced by Dexamethasone.
WO2024229265A2 (en) Identification of mechanosensing regulators in plasmacytoid dendritic cells
Silvestre The role of post-translational modifications on STAT3 interactions
HK40009351A (en) Compounds for treatment of diseases related to dux4 expression
HK40009351B (en) Compounds for treatment of diseases related to dux4 expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110824